Joep J de Jong

9PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 31, 2026
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

|May 27, 2026
Proceedings of the first international NMIBC consensus classification meeting.

|Jul 15, 2025
Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy.

Joep J de Jong, Moritz J Reike, Yair Lotan

|Jun 20, 2025
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Valentina Tateo, Joep J de Jong, Antonio Cigliola

|Nov 01, 2024
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.

Joep J de Jong, James A Proudfoot, Siamak Daneshmand

|Oct 28, 2024
Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy.

Min Woo Hwang, Jasmine Kauffeld, Sarah Belay

Pageof 2

Frequent Collaborators

3 joint publications

Andrea Necchi

3 joint publications

Elai Davicioni

2 joint publications

Ewan A Gibb

2 joint publications

Emanuele Crupi